Irinotecan Mylan (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Mylan, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic colorectal cancer and advanced solid tumors in adult patients.

GNH USA supplies Irinotecan Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan Mylan is a topoisomerase I inhibitor used in oncology for several cancer types.

- Metastatic colorectal cancer: improves overall survival when combined with fluoropyrimidine‑based regimens. - Advanced solid tumors: provides antitumor activity in a range of refractory solid malignancies. - Colorectal cancer (adjuvant setting): used as part of combination therapy to reduce recurrence risk after surgical resection.

Irinotecan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset common during infusion. - Diarrhea: may be severe and require antidiarrheal therapy. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: temporary hair loss during treatment. - Fatigue: general tiredness and weakness. - Anemia: decreased red blood cell levels causing fatigue.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils requiring urgent care. - Severe colitis: inflammation of the colon that can be life‑threatening. - Hepatotoxicity: liver enzyme elevations indicating liver injury. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis during infusion. - Cardiac toxicity: rare arrhythmias or ischemic events. - Secondary malignancies: very rare risk of new cancers after prolonged exposure.

Before initiating therapy, clinicians should assess patient health status and monitor for specific risks.

- Baseline blood counts: obtain CBC to detect pre‑existing neutropenia or anemia. - Liver function: evaluate hepatic enzymes as irinotecan metabolism is hepatic. - Renal function: adjust monitoring if creatinine clearance is impaired. - Concomitant medications: review for drugs that may increase toxicity, especially CYP3A4 inhibitors. - Pregnancy and lactation: avoid use unless benefits clearly outweigh potential fetal or infant risks. - Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Irinotecan can interact with several drug classes, altering efficacy or toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase SN‑38 exposure and toxicity. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Anticholinergic agents: can exacerbate irinotecan‑induced diarrhea.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels, increasing risk of neutropenia. - Other myelosuppressive chemotherapy: may compound bone‑marrow suppression, necessitating frequent blood count checks.